A 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to access the efficacy, safety and tolerability of two doses of indacaterol (selected from

  • Doherty, Dennis (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/078/31/09